Company / Current Assets
Arbutus Biopharma Corp Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$94.5M
FY2025
5-year range
$94.5M / $160.7M
FY2021-FY2025
Trend
-25.8%
vs FY2024
Sector context
#205 of 213
Health Care
What the data says
Among 213 Health Care companies, Arbutus Biopharma Corp is in the bottom 4% for current assets. Current Assets has declined for 4 consecutive years, from $161M in FY2021 to $94M in FY2025.
Based on SEC 10-K filings.
$94M in FY2025 with a 5-year CAGR of -5.9%.
Declined from $132M to $94M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -14.5%
- 5-Year CAGR
- -5.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 213This company $94.5M Sector average $2.5B
▼
-96.3% below sector average
Key checks
Key Insights
- Arbutus Biopharma Corp's current assets has declined for 4 consecutive years.
- 5-year CAGR of -5.9%, indicating a declining trend.
- In FY2025, current assets decreased 25.8% year-over-year.
- Ranks #205 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $94.5M | -25.8% |
| FY2024 | $127.3M | -3.6% |
| FY2023 | $132.0M | -12.6% |
| FY2022 | $151.1M | -5.9% |
| FY2021 | $160.7M | +25.8% |
| FY2020 | $127.7M | +36.1% |
| FY2019 | $93.8M | -27.4% |
| FY2018 | $129.2M | -0.1% |
| FY2017 | $129.4M | -2.4% |
| FY2016 | $132.6M | -27.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026